Skip to main content

Angion Biomedica shares dive after kidney-disease drug trial discontinued

Angion Biomedica Corp. shares dived 30% to $1.20 in after-hours trading Wednesday after the company said it is discontinuing a Phase 2 trial of ANG-3070 in patients with primary proteinuric kidney diseases.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.